| EBCCP Program Areas |
Example Primary Study Outcomes*‡ |
| *Eligible outcomes may be collected via self-report or observation, and whenever possible, use of biologic samples (e.g., blood or urine) or healthcare administrative data (e.g., chart review, EHR data pulls) are encouraged.
‡ Use of validated measures for study outcomes is strongly encouraged. Examples of validated data collection tools: PhenX Toolkit (with alcohol, tobacco, and other measures), Dietary Assessment Research Resources, Physical Activity Assessment Resources, and Group-Evaluated Measures.
|
| Alcohol Use
| - Prevention of alcohol use initiation – Follow-up at 12 months minimum
- Increase alcohol abstinence (e.g., percentage of days abstinent, duration of abstinence) – Follow-up at 3 months minimum
- Reduction in alcohol consumption quantity, frequency, or intensity (e.g., drinks per drinking day, drinks per day, percentage of heavy drinking days) – Follow-up at 3 months minimum
|
| Cancer Screening: Breast, Cervical, Colorectal
| - Improvements in guideline-concordant screening uptake and/or adherence or other behavioral outcomes (e.g., scheduling an appointment)
|
| Cancer Screening: Lung
| - Improvements in guideline-concordant screening uptake and/or adherence
- Improvements in other behavioral and/or psychosocial outcomes (e.g., preference or values alignment, improved communication, decisional satisfaction or conflict, scheduling an appointment)
- Improvements in cognitive outcomes (e.g., knowledge, awareness, risk perception)
|
| Cancer Screening: Prostate
| - Improvements in behavioral and/or psychosocial outcomes (e.g., preference or values alignment, improved communication, decisional satisfaction or conflict, opting for or against a given clinical service)
- Improvements in cognitive outcomes (e.g., knowledge, awareness, risk perception.)
|
| Cancer Screening: Follow-up to Abnormal Screening Results
| - Improvements in adherence to appropriate follow-up evaluation and/or testing (e.g., biopsy, colonoscopy after abnormal stool test, cytology or colposcopy after positive HPV test or abnormal Pap) and timeliness of follow-up
|
| Cancer Survivorship
| - Increase in survival time, health-related quality of life; decrease in pain or suffering
- Improvements in behavioral and/or psychosocial outcomes (e.g., anxiety, depression, stress, mood, self-efficacy, use of coping techniques, improved communication, decreased uncertainty)
- Improvements in cognitive outcomes (e.g., mental functioning, memory, knowledge, risk perception)
|
| Diet & Nutrition
| - Improvements in dietary and nutritional intake (e.g., fruit and vegetable consumption, reductions in calories from total fats and saturated fats, consumption of sugar-sweetened beverages)
|
| Genetic & Genomic Testing
| - Improvements in behavioral and/or psychosocial outcomes (e.g., decisional satisfaction or conflict, opting for recommended genetic services, notification of family members for cascade testing)
- Improvements in cognitive outcomes (e.g., knowledge, awareness, risk perception)
|
| HPV Vaccination
| - Improvements in HPV vaccine initiation and/or series completion
- Improvements in provider communication with parents and/or patients
|
| Obesity Management
| - Improvements in anthropometric measures (e.g., weight, BMI, waist circumference)
|
| Physical Activity
| - Improvements in physical activity (e.g., minutes of moderate to vigorous physical activity or exercise, reductions in sedentary behaviors)
|
| Sun Safety & Indoor Tanning
| - Improvements in ultraviolet radiation safety behaviors (e.g., use of sunscreen, avoidance of indoor tanning)
|
| Tobacco Control
| - Prevention of tobacco use initiation – Follow-up at 12 months minimum
- Increase in 7-day point-prevalence abstinence or continuous abstinence – Follow-up at 6 months minimum, biologic verification strongly encouraged
- Reduction in secondhand smoke exposure (e.g., decrease in ambient nicotine level, increase in indoor smoking bans)
|
